Iterum Therapeutics (ITRM) Free Cash Flow (2017 - 2022)
Historic Free Cash Flow for Iterum Therapeutics (ITRM) over the last 6 years, with Q4 2022 value amounting to -$4.3 million.
- Iterum Therapeutics' Free Cash Flow fell 7435.28% to -$4.3 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$18.5 million, marking a year-over-year decrease of 1684.01%. This contributed to the annual value of -$26.8 million for FY2024, which is 3195.23% up from last year.
- According to the latest figures from Q4 2022, Iterum Therapeutics' Free Cash Flow is -$4.3 million, which was down 7435.28% from -$4.5 million recorded in Q3 2022.
- Over the past 5 years, Iterum Therapeutics' Free Cash Flow peaked at -$1.1 million during Q1 2021, and registered a low of -$27.5 million during Q3 2018.
- Over the past 5 years, Iterum Therapeutics' median Free Cash Flow value was -$10.3 million (recorded in 2018), while the average stood at -$12.4 million.
- In the last 5 years, Iterum Therapeutics' Free Cash Flow crashed by 39214.67% in 2018 and then surged by 9586.73% in 2021.
- Over the past 5 years, Iterum Therapeutics' Free Cash Flow (Quarter) stood at -$25.2 million in 2018, then grew by 8.54% to -$23.1 million in 2019, then skyrocketed by 60.83% to -$9.0 million in 2020, then surged by 72.63% to -$2.5 million in 2021, then plummeted by 74.35% to -$4.3 million in 2022.
- Its last three reported values are -$4.3 million in Q4 2022, -$4.5 million for Q3 2022, and -$6.3 million during Q2 2022.